RAPT Therapeutics, Inc.
8
1
1
3
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 80/100
50.0%
4 terminated/withdrawn out of 8 trials
42.9%
-43.6% vs industry average
0%
0 trials in Phase 3/4
100%
3 of 3 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (8)
Phase 2b Study of RPT904 as Monotherapy in Participants With IgE-Mediated Food Allergy
Role: lead
Phase 2 Study to Evaluate RPT193 in Adults With Moderate to Severe T2-high Asthma
Role: lead
An Efficacy and Safety Study of RPT193 in Adults With Atopic Dermatitis
Role: lead
Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination with Pembrolizumab
Role: lead
FLX475 in Combination With Ipilimumab in Advanced Melanoma
Role: lead
Study of RPT193 in Healthy Adult Male Subjects
Role: lead
A First-in-Human Study of RPT193 in Healthy Volunteers and Patients With Atopic Dermatitis
Role: lead
First-in-Human Study of FLX925 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia
Role: lead
All 8 trials loaded